Transient elastography discloses identical distribution of liver fibrosis in chronic hepatitis C between HIV-negative and HIV-positive patients on HAART

European Journal of Medical Research

Volumn 15, Issue 4, 2010, Pages 139-144

  Grunhage F ^a,b   Wasmuth, J C ^a   Herkenrath, S ^a   Vidovic, N ^a   Goldmann, G ^a   Rockstroh, J ^a   Lammert, F ^b   Oldenburg, J ^a   Sauerbruch, T ^a   Spengler, Ulrich ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

HCV; HIV; Liver fibrosis; Transelastography

Indexed keywords

RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; CROSS-SECTIONAL STUDY; DISEASE COURSE; ELASTOGRAPHY; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTPATIENT DEPARTMENT; RIGIDITY; TREATMENT DURATION; CHRONIC HEPATITIS C; CONTROLLED STUDY; DIGESTIVE TRACT PARAMETERS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIVER STIFFNESS; PROSPECTIVE STUDY; TRANSIENT ELASTOGRAPHY;

EID: 77952035641     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-15-4-139     Document Type: Article

References (31)

1. Lanternier F, Roulot D, Bentata M, Pol S, Viard JP, Gordien E, Jeantils V, Ziol M, Lortholary O. Risks factors of liver fibrosis in a cohort of intravenous drug users coinfected with HIV and HCV in the HAART era: the role of mixed steatosis. Gastroenterol Clin Biol. 2007 Oct; 31(10): 822-827
2. Monto A, Kakar S, Dove LM, Bostrom A, Miller EL, Wright TL. Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients. Am J Gastroenterol. 2006 Jul; 101(7): 1509-1515 (Pubitemid 43980624)
3. Barreiro P, Martin-Carbonero L, Nunez M, Rivas P, Morente A, Simarro N, Labarga P, Gonzalez-Lahoz J, Soriano V. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3. Clin Infect Dis. 2006 Apr 1; 42(7): 1032-1039
4. Schiavini M, Angeli E, Mainini A, Zerbi P, Duca PG, Gubertini G, Vago L, Fociani P, Giorgi R, Cargnel A. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. HIV Med. 2006 Jul; 7(5): 331-337
5. Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, Mehta S, Kirk GD, Nelson K, Afdhal N, Thomas DL. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology. 2006 Apr; 43(4): 788-795
6. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, Katlama C, Poynard T. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology. 2001 Aug; 34(2): 283-287
7. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, Paradis V, Vidaud M, Valla D, Bedossa P, Marcellin P. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008 Feb; 134(2): 416-423
8. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004 Mar; 53(3): 451-455
9. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol. 2002 Sep; 97(9): 2408-14.
10. Franchini M, Rossetti G, Tagliaferri A, Capra F, de Maria E, Pattacini C, Lippi G, Lo Cascio G, de Gironcoli M, Gandini G. The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. Blood. 2001 Sep 15; 98(6): 1836-1841
11. Rockstroh JK, Spengler U, Sudhop T, Ewig S, Theisen A, Hammerstein U, Bierhoff E, Fischer HP, Oldenburg J, Brackmann HH, Sauerbruch T. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gas-troenterol. 1996 Dec; 91(12): 2563-2568 (Pubitemid 126733798)
12. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, Rey C, Abad MA, Rodriguez M, Sales Gilabert M, Gonzalez F, Miron P, Caruz A, Relimpio F, Torronteras R, Leal M, Lissen E. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997 Jan; 26(1): 1-5. (Pubitemid 27072597)
13. Sanchez-Quijano A, Andreu J, Gavilan F, Luque F, Abad MA, Soto B, Munoz J, Aznar JM, Leal M, Lissen E. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis. 1995 Nov; 14(11): 949-953
14. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Dusheiko GM, Lee CA, Ludlam CA, Preston FE. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet. 1997 Nov 15; 350(9089): 1425-1431
15. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A, Bedossa P. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003 Mar; 38(3): 257-265 (Pubitemid 36286537)
16. Macias J, Mira JA, Lopez-Cortes LF, Santos I, Giron-Gonzalez JA, Gonzalez-Serrano M, Merino D, Hernandez-Quero J, Rivero A, Merchante N, Trastoy M, Carrillo-Gomez R, Arizcorreta-Yarza A, Gomez-Mateos J, Pineda JA. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir Ther. 2006; 11(7): 839-846
17. Tural C, Fuster D, Tor J, Ojanguren I, Sirera G, Ballesteros A, Lasanta JA, Planas R, Rey-Joly C, Clotet B. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat. 2003 Mar; 10(2): 118-125
18. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK, Spengler U. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003 Nov 22; 362(9397): 1708-1713
19. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003 Dec; 38(6): 1449-1457
20. Pinzani M, Vizzutti F, Arena U, Marra F. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol. 2008 Feb; 5(2): 95-106.
21. Nattermann J, Vogel M, Berg T, Danta M, Baumgarten A, Mayr C, Bruno R, Tural C, Klausen G, Clotet B, Lutz T, Grunhage F, Rausch M, Nischalke HD, Schewe K, Bienek B, Haerter G, Sauerbruch T, Rockstroh JK, Spengler U. Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology. 2007 Oct; 46(4): 1016-1025
22. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003 Aug; 38(2): 518-526
23. Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology. 2008 Feb; 47(2): 592-595
24. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007 Jul; 56(7): 968-973
25. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003 Dec; 29(12): 1705-1713
26. Brau N, Salvatore M, Rios-Bedoya CF, Fernandez-Carbia A, Paronetto F, Rodriguez-Orengo JF, Rodriguez-Torres M. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 2006 Jan; 44(1): 47-55. (Pubitemid 41772515)
27. Souza AR, Tovo CV, Mattos AA, Chaves S. There is no difference in hepatic fibrosis rates of patients infected with hepatitis C virus and those co-infected with HIV. Braz J Med Biol Res. 2008 Mar; 41(3): 223-228 (Pubitemid 351761076)
28. Spivak JL, Bender BS, Quinn TC. Hematologic abnormalities in the acquired immune deficiency syndrome. Am J Med. 1984 Aug; 77(2): 224-228 (Pubitemid 14098629)
29. de Ledinghen V, Barreiro P, Foucher J, Labarga P, Castera L, Vispo ME, Bernard PH, Martin-Carbonero L, Neau D, Garcia-Gasco P, Merrouche W, Soriano V. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat. 2008 Jun; 15(6): 427-433
30. Valle Tovo C, Alves de Mattos A, Ribeiro de Souza A, Ferrari de Oliveira Rigo J, Lerias de Almeida PR, Galperim B, Riegel Santos B. Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus. Liver Int. 2007 Feb; 27(1): 40-46
31. Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M, Rios-Villegas MJ, Ruiz-Morales J, Rivero A, del Valle J, Luque R, Rodriguez-Bano J, Gonzalez-Serrano M, Camacho A, Macias J, Grilo I, Gomez-Mateos JM. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology. 2007 Sep; 46(3): 622-630